$21.48
0.361.73%
Dern. MÀJ: Nov 13, 11:04 AM
Takeda Pharmaceutical rose 48.3% from $14.24 to $21.12, ahead of the S&P 500's +12.7%. Its worst day was Jun 1 (−4.8%), and its low came Nov 20 at $14.06.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Takeda Pharmaceutical closed at its lowest level of the year, 1.3% below where the year started.
−0.2% · S&P 500 −1.5%
EPS of $0.47 missed the $0.55 estimate on $7.6B revenue (est. $8.5B); FY revenue guidance of $29.4B against the $28.5B consensus.
Story events cover the past 12 months · Times ET
+2.9% · S&P 500 −0.2%
EPS of $0.28 beat the $0.21 estimate on $7.0B revenue (est. $7.0B); FY revenue guidance of $29.6B against the $28.9B consensus.
+1.3% · S&P 500 +0.6%
Takeda Pharmaceutical shares fell 4.8%, while the S&P 500 rose 0.3%.
−4.8%, the year's worst day · S&P 500 +0.3%
Takeda Pharmaceutical shares rose 5.1%, while the S&P 500 fell 0.1%.
+5.1%, the year's best day · S&P 500 −0.1%
EPS of $0.48 beat the $0.39 estimate on $7.7B revenue (est. $7.1B); FY revenue guidance of $29.6B against the $28.9B consensus.
−2.8% · S&P 500 +1.7%
Takeda Pharmaceutical shares rose 3.9%, while the S&P 500 fell 0.7%.
+3.9% · S&P 500 −0.7%
EPS of $0.48 beat the $0.31 estimate on $7.5B revenue (est. $7.2B); FY revenue guidance of $29.5B against the $28.9B consensus.
−0.7% · S&P 500 −0.4%
Where it ended: a close of $21.12 on Nov 12, 2026. Up next: Q3 2026 earnings on Jan 28, 2027 (EPS est. $0.45, revenue est. $7.7B).
Nothing in the past 12 months.
All TAK analyst actionsReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TAK and SPY from Benzinga historical bars. Not investment advice.